Tier 4 of the offering has officially closed and we have qualification from the SEC to sell our shares at the price of $8.20 per share. We […]
Tier 4 of the offering has officially closed and we have qualification from the SEC to sell our shares at the price of $8.20 per share. We […]
Special Guest Dr. Jake Hutchins will join us for a wide ranging discussion with Q&A on state of the art in Post-Operative Pain Control. We will also […]
Join us for a veterinarian webcast with Stacie Lipinski, DVM, and Jim Segermark, CEO of InSitu Biologics on Tuesday, June 11th 8:30PM EST / 5:30PM PST. They will discuss […]
We’re hosting a get together to network and have Dr. Jake Hutchins MD, Executive Medical Director at M Health Ambulatory Surgery Center, discuss the advancements made within […]
I hope this letter finds you off to a great 2019. To receive timely information on your Company, please check back here or head on over to […]
Casual conversation, drinks, appetizers & NCAA Sweet 16 Hoops Thursday, March 28th | 5-?? PM D’Arcy’s Tavern – Bradley Beach, NJ* *Reservation Required RSVP: https://www.eventbrite.com/e/investing-in-biotech-investors-for-non-opiate-pain-solutions-dinner-tickets-58183002928
Join Us for Lunch & an Investment Presentation Monday, April 8 or Tuesday, April 9 11:30 – 2:00 each day Naples Beach Hotel & Golf Club* *Reservation […]
The government shutdown in December and January has caused a tremendous backlog of quarterly and year-end filings for review at the SEC. Accordingly, our updated RegA+ Offering […]
I hope this note finds you off to a great 2019. We are pleased to announce that InSitu Biologics Stock Offering will again open on Wednesday, January […]
WOODBURY, Minn., Dec. 4, 2018 /Press Release/ — InSitu Biologics, Inc., an emerging biotech company focusing on the development of AnestaGel™, has received over $2 million in […]